This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) shares fell about 4% on Friday after data indicated its obesity drug prescriptions were trailing those of rival Novo Nordisk. Eli Lill⦠[+859 chars]
No comments yet. Be the first to comment!